Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Next Previous
Search
Trial Profile

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; NUV 868 (Primary) ; Olaparib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Peritoneal cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Nuvation Bio

    • Most Recent Events

    • 29 Feb 2024 According to a Nuvation Bio media release, Nuvation Bio has completed the Phase 1 monotherapy study in advanced solid tumors and determined the MTD in patients, Phase 1b combination studies remain ongoing
    • 02 May 2023 Planned number of patients changed from 246 to 657.
    • 02 May 2023 Planned End Date changed from 1 Feb 2026 to 1 Nov 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top